Syschem
46.35
+0.29(+0.63%)
Market Cap₹201.66 Cr
PE Ratio24.37
IndustryHealthcare
Company Performance:
1D+0.63%
1M-11.78%
6M-14.58%
1Y+15.50%
5Y+480.10%
View Company Insightsright
More news about Syschem
03Feb 26
Syschem India Q3FY26 Net Profit Surges 729% YoY to ₹417.08 Lakhs, Board Approves ₹14 Crore Plant Expansion
Syschem India Limited reported outstanding Q3FY26 results with net profit jumping 729% YoY to ₹417.08 lakhs and revenue increasing 77% to ₹16,164.21 lakhs. The company's Board approved a ₹14 crore plant expansion at Village Bargodam for manufacturing Amoxicillin and Ampicillin, expected to be commissioned by December 2026. The company also fulfilled regulatory compliance by publishing financial results in newspapers as per SEBI requirements.
 no imag found
02Feb 26
Syschem India Limited Reports Strong Growth with 65% Revenue Increase in 9M FY25-26
Syschem India Limited reported exceptional financial performance in 9M FY25-26 with revenue growth of 65% to ₹40,631 lakhs from ₹24,748 lakhs in the previous year. The pharmaceutical API manufacturer achieved remarkable profitability improvements with EBITDA growth of 312% and PAT growth of approximately 858%. Export sales reached ₹107.62 crore, exceeding full-year FY24-25 exports, while Q3 FY25-26 showed 177% revenue growth. The company operates with 4,200 TPA capacity serving 100+ global customers across 3 continents.
 no imag found
02Feb 26
Syschem India Board Approves ₹140 Million Manufacturing Unit Expansion
Syschem (India) board has approved a significant manufacturing unit expansion worth approximately ₹140 million. This strategic investment demonstrates the company's commitment to enhancing production capabilities and scaling operations. The board's approval marks a major milestone in the company's growth strategy and infrastructure development.
 no imag found
05Jan 26
Syschem India Ltd Commences Commercial Production of New Manufacturing Units
Syschem India Ltd has successfully commenced commercial production of two key manufacturing units. The company launched an expanded Amoxicillin unit with 1200 MT capacity on January 5, 2026, and a new Cloxacillin unit with 600 MT capacity. These developments significantly enhance the pharmaceutical company's manufacturing capabilities and production capacity in essential antibiotic segments.
 no imag found
11Nov 25
Syschem India Reports Net Loss of Rs 60.54 Crore in Q2 FY2026
Syschem (India) Limited announced unaudited financial results for Q2 FY2026, reporting a net loss of Rs 60.54 crore, compared to a profit of Rs 67.18 crore in the previous quarter. Revenue from operations decreased to Rs 1,179.24 crore from Rs 1,267.58 crore. For the half-year ending September 30, 2025, the company recorded a loss of Rs 422.07 crore before tax. Total assets stood at Rs 2,172.62 crore, with total equity at Rs 948.60 crore. Trade receivables and inventories decreased to Rs 697.03 crore and Rs 413.24 crore respectively.
 no imag found
22Oct 25
Syschem India Settles ₹5.18 Crore Legal Case with QP Pharmachem
Syschem India Limited has resolved a legal dispute with QP Pharmachem, involving a total settlement of ₹5.18 crore. The case, filed under Section 138 of the Negotiable Instruments Act, has been dismissed as withdrawn. Syschem has already paid ₹3.95 crore, with a contingent payment of ₹1.23 crore issued as a cheque. This contingent amount is subject to potential dollar exchange rate differences for remittance to a Chinese entity. The settlement order was received on October 22, 2025, from the Chief Judicial Magistrate - 1st Class, Taluka Court, Derabassi.
 no imag found
29Sept 25
Syschem (India) Unveils Ambitious Expansion Plan for Antibiotic Production
Syschem (India) Limited announces significant expansion of its antibiotic production capabilities. The company's board has approved plans for a new factory to produce Cloxacillin, Dicloxacillin, and Flucloxacillin Sodium, as well as the expansion of its existing amoxicillin unit. The total investment is estimated at Rs. 15.00 to 20.00 Crore, financed through internal accruals or debt funding. The expansion will add 1,600.00 TPA to the current plant capacity of 2,400.00 TPA. The project is expected to be completed by December 2025, aiming to improve operational efficiency, strengthen product portfolio, and meet growing customer demand.
 no imag found
12Sept 25
Syschem (India) Limited Wins Litigation Case, Faces Rs 15.00 Lakh Financial Impact
Syschem (India) Limited, a BSE-listed company, has successfully concluded a legal case filed by Shri Shubham Road Carer. The City Civil Court in Secunderabad dismissed the suit as the plaintiff filed a memo stating it was not being pursued. Despite the favorable outcome, Syschem faces a total financial impact of Rs 15 lakh, comprising Rs 9,14,545 as principal amount and Rs 5,85,455 in litigation costs and interest. The company has duly informed BSE Limited about the case's disposal in compliance with SEBI regulations.
 no imag found
04Aug 25
Syschem India Reports 24% Revenue Growth in Q1, Expands Production Capacity
Syschem India Limited reported robust Q1 results with total income reaching ₹126.76 crore, a 24% increase year-over-year. Profit before tax surged by 1124% to ₹1.67 crore. The company achieved an 81% increase in production capacity and is constructing a new WHO-GMP compliant manufacturing unit in Kalka, Haryana. Syschem has expanded its presence across 12 Indian states and several international markets. The board made key appointments to strengthen corporate governance and granted stock options to key employees.
 no imag found
Syschem
46.35
+0.29
(+0.63%)
1 Year Returns:+15.50%
Industry Peers
Sun Pharmaceutical
1,801.60
(-1.30%)
Divis Laboratories
6,071.00
(-3.36%)
Torrent Pharmaceuticals
4,390.00
(-1.26%)
Dr Reddys Laboratories
1,292.30
(-2.02%)
Cipla
1,314.70
(-0.72%)
Lupin
2,314.90
(-1.80%)
Zydus Life Science
905.90
(-1.20%)
Mankind Pharma
2,138.90
(-3.13%)
Aurobindo Pharma
1,296.50
(-1.17%)
Alkem Laboratories
5,355.50
(-1.63%)